NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies
NanoViricides Inc. announced that its clinical lead drug, NV-387, has demonstrated strong antiviral activity against the Measles virus in both cell culture studies and a humanized animal model. The company reported that NV-387 treatment led to protection of lung tissue, an important outcome for patients with severe viral infections. According to NanoViricides, NV-387 has completed a Phase I clinical trial in healthy subjects, showing no reportable adverse events and was found to be safe and well tolerated. The company highlighted that NV-387 is a multi-purpose, broad-spectrum antiviral currently being developed for several respiratory viral infections, including RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, MPox, and Smallpox. Results from the studies have already been presented. NanoViricides is seeking additional funding to support further development of NV-387 as a treatment for Measles.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1090472) on October 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.